MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Georgian medical news · 2026

EFFICACY OF PERINDOPRIL IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION.

Nazghaidze N, Petriashvili Sh, Agladze R, Kuridze N, Kereselidze Z, Ungiadze S

СтатьяПеревод в очереди

Аннотация

BACKGROUND/

INTRODUCTION

Heart failure with reduced ejection fraction (HFrEF) represents a major global health burden, accounting for approximately half of all heart failure cases and characterized by high mortality, frequent hospitalizations, and progressive cardiac remodeling. Angiotensin-converting enzyme (ACE) inhibitors constitute a foundational cornerstone in the therapeutic management of HFrEF. Perindopril is a long-acting ACE inhibitor with a highly favorable safety profile; however, robust clinical data evaluating its specific efficacy in HFrEF cohorts remain scarce.

AIM: To evaluate the therapeutic efficacy, reverse cardiac remodeling, and clinical outcomes of perindopril versus sacubitril/valsartan in patients with HFrEF in routine clinical practice.

METHODS

This retrospective cohort study included 214 HFrEF patients (LVEF<40%, mean age 64.8±11.0 years) treated at Tbilisi Heart Center between 2018 and 2025. Patients received GDMT and were divided into two groups: Perindopril (n=118) and Sacubitril/Valsartan (n=96). Clinical, echocardiographic, and biochemical metrics were assessed at baseline (Visit 1), 2-3 weeks (Visit 2), and 3-6 months (Visit 3). Primary endpoints included changes in LVEF and NYHA functional class.

RESULTS

• Both treatment strategies significantly improved LVEF, reduced left ventricular dimensions (LVEDD, LVESD), and decreased pulmonary artery systolic pressure (ANOVA p < 0.01), with major reverse remodeling occurring between Visits 1 and 2. • LVEF increased from 34.3±3.9% to 41.3±7.4% in the perindopril group and from 30.8±5.2% to 33.8±8.1% in the sacubitril/valsartan group. • In multivariable linear regression analysis, treatment group (B=-3.170, p=0.004), baseline LVEF (B=0.381, p=0.005), and de novo heart failure (B=2.966, p=0.005) were independent predictors of follow-up LVEF. • Both cohorts showed significant longitudinal optimization in NYHA functional class (p<0.001). No significant changes in serum potassium or renal function were observed. One-year all-cause mortality did not differ significantly between groups (33.1% vs. 22.9%, p=0.103).

CONCLUSION

Perindopril therapy is associated with significant clinical improvement, LVEF recovery, and positive reverse cardiac remodeling in patients with HFrEF. Both perindopril and sacubitril/valsartan demonstrate comparable efficacy in reducing cardiac dimensions and optimizing NYHA functional status. Furthermore, perindopril maintains a favorable safety profile with low nephrotoxicity, confirming its potential as an effective therapeutic option in HFrEF management.

Для цитирования: Nazghaidze N, Petriashvili Sh, Agladze R, Kuridze N, Kereselidze Z, Ungiadze S. EFFICACY OF PERINDOPRIL IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION.. Georgian medical news. 2026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.